Hyperlipidemia

Metabolic·MeSH: Hyperlipidemias

11 drugs in development·8 companies·4 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
colesevelam	Impax Laboratories, LLC (IPXL)
fenofibrate	Amneal Pharmaceuticals, Inc. (AMRX)
nexletol	Esperion Therapeutics, Inc. (ESPR)
nexlizet	Esperion Therapeutics, Inc. (ESPR)
pitavastatin	Mylan II B.V. (MYL)

Phase 3(3)

Drug	Company
Enlicitide	Merck & Co., Inc. (MRK)
Rosuvastatin	Merck & Co., Inc. (MRK)
syh2053	NYMOX PHARMACEUTICAL CORP (NYMXF)

N/A(1)

Drug	Company
Niacin	Cidara Therapeutics, Inc. (CDTX)

Phase 1/Phase 2(2)

Drug	Company
ARO-DIMER-PA	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARO-DIMERPA	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

BioSniper tracks 11 drugs in development for Hyperlipidemia across 8 companies.

There are 4 clinical trials targeting Hyperlipidemia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.